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Background: The myocardial effects of phosphodiesterase type 5 inhibitors (PDE5i) have recently received
consideration in several preclinical studies. The risk/benefit ratio in humans remains unclear.
Methods: We performed a meta-analysis of randomized, placebo-controlled trials (RCTs) to evaluate the efficacy
and safety of PDE5i on cardiac morphology and function. From March 2012 to December 2013 (update: May 2014),
we searched English-language studies from MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and
SCOPUS-selecting RCTs of continuous PDE5i administration that reported cardiovascular outcomes: cardiac geometry
and performance, afterload, endothelial function and safety. The pooled estimate of a weighted mean difference
between treatment and placebo was obtained for all outcomes using a random effects model. A test for heterogeneity
was performed and the I2 statistic calculated.
Results: Overall, 1,622 subjects were treated, with 954 randomized to PDE5i and 772 to placebo in 24 RCTs. According
to our analysis, sustained PDE5 inhibition produced: (1) an anti-remodeling effect by reducing cardiac mass (−12.21
g/m2, 95% confidence interval (CI): −18.85; −5.57) in subjects with left ventricular hypertrophy (LVH) and by increasing
end-diastolic volume (5.00 mL/m2; 95% CI: 3.29; 6.71) in non-LVH patients; (2) an improvement in cardiac performance
by increasing cardiac index (0.30 L/min/m2, 95% CI: 0.202; 0.406) and ejection fraction (3.56%, 95% CI: 1.79; 5.33). These
effects are parallel to a decline of N-terminal-pro brain natriuretic peptide (NT-proBNP) in subjects with severe LVH
(−486.7 pg/ml, 95% CI: −712; -261). PDE5i administration also produced: (3) no changes in afterload parameters and
(4) an improvement in flow-mediated vasodilation (3.31%, 95% CI: 0.53; 6.08). Flushing, headache, epistaxis and gastric
symptoms were the commonest side effects.
Conclusions: This meta-analysis suggests for the first time that PDE5i have anti-remodeling properties and improve
cardiac inotropism, independently of afterload changes, with a good safety profile. Given the reproducibility of
the findings and tolerability across different populations, PDE5i could be reasonably offered to men with cardiac
hypertrophy and early stage heart failure. Given the limited gender data, a larger trial on the sex-specific
response to long-term PDE5i treatment is required.
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For many years, the use of selective phosphodiesterase
type 5 inhibitors (PDE5i) has been limited to on-demand
administration for erectile dysfunction (ED) [1]. These
drugs have recently been shown to affect hemodynamics,
right heart performance and oxygenation in patients with
pulmonary arterial hypertension (PAH) [2-4]. In addition,
PDE5i are currently used in continuous administration for
rehabilitation of erectile function and relief of lower
urinary tract symptoms [5], although their systemic effects
and safety have not been formally appraised.
Initial studies on PDE5i investigated their possible
use in the symptomatic relief of angina. However, this
was soon abandoned due to the risk of coronary steal
or hypotension. Nevertheless, the potential role of
PDE5i in non-urological fields continued to attract
interest [6,7]. In parallel, several preclinical experimental
studies demonstrated that PDE5i were beneficial in
ischemia/reperfusion injury, myocardial infarction,
doxorubicin-induced cardiotoxicity, hypertrophic cardiac
remodeling and heart failure (HF) [8,9]. All these condi-
tions share an enhanced expression of PDE5 enzyme in
cardiomyocytes.
Despite these promising animal data, the cardiopro-
tective effect of PDE5i in humans remained unclear. Of
note is the discrepancy between the amount of solid
experimental data and the paucity of translational
studies for drugs that are readily available and widely
used with other indications. The few human studies
primarily targeting specific cardiac conditions - post-
myocardial infarction diastolic dysfunction, diabetic
cardiomyopathy, mild and severe heart failure [10-13] -
suggest a potential effect of PDE5i on cardiac kinetics,
geometry and performance, although not universally
[14]. Controversy also exists concerning the claimed
mechanisms: some hypothesized a direct effect within
cardiomyocytes [11,12], some suggested coronary [15]
and peripheral vasodilation [16] and yet others a peripheral
endothelial effect [17]. However, a much larger number of
trials is available reporting cardiac outcomes as secondary
endpoints after continuous PDE5i administration.
We performed this meta-analysis to investigate whether
chronic PDE5 inhibition modulates cardiac parameters in
different clinical settings, exploring both cardiac and
peripheral vascular effects, since these endpoints have
never been fully assessed in a comprehensive review of
the literature.
Specially, we aimed to answer the following questions:
‘Does chronic administration of PDE5i produce clin-
ically meaningful changes in cardiac remodeling and
performance?’, ‘Does chronic administration of PDE5i
produce hemodynamic and/or endothelial function
changes?’, ‘Is chronic PDE5i administration well-tolerated
and safe?’Methods
We performed this study according to the Cochrane
Collaboration and PRISMA statement [18].Data sources and searches
From March 2012 to December 2013 we searched
for English-language articles in MEDLINE, EMBASE,
Cochrane Library and SCOPUS. Search terms were:
sildenafil/tadalafil/vardenafil/PDE5i AND hypertension/
blood pressure/pulmonary hypertension/cardiovascular
disease/ heart/heart failure/endothelium/endothelial func-
tion. We updated the search in May 2014, but no further
studies were included.Study selection
Eligibility criteria for study selection included: 1) random-
ized placebo-controlled trials (RCTs); and 2) chronic PDE5i
administration defined as a continuous, daily or alternate
day (for tadalafil only based on its half-life), prolonged
(≥4 weeks) administration. We selected studies reporting
any cardiovascular outcomes (as primary or secondary
endpoint) independently of the baseline characteristics of
the study population.
We excluded reviews, editorials, commentaries, letters,
non-RCTs, animal studies, co-administration of PDE5i
with other therapies (that is, endothelin antagonist or
bosentan) or measuring outcomes under stress or under
hypoxic conditions.
Three independent reviewers evaluated all selected
titles and abstracts, and for articles considered potentially
eligible, full text reports were considered. Interobserver
agreement was high (98%: 434/441 RCTs chosen for full
text analysis). Where disagreement occurred, a unanimous
decision was taken after open discussion. Figure 1 shows
the literature eligibility assessment process.Data extraction and quality assessment
Two reviewers (T.F. and R.P.) independently extracted
data on study design, sample population (age, gender,
clinical status, comorbidities) and treatment character-
istics (active compound: sildenafil, tadalafil, vardenafil;
dosage and length of treatment). Table 1 summarizes
the features of selected studies [see also Additional file 1:
Table S1].
In order to compare all studies on the effect of the
treatment at the end of the planned therapeutic cycle,
we excluded ad interim data, and only end-of-treatment
values were recorded. The third investigator (E.G.) per-
formed quality control checks on extracted data. Risk
of bias for all trials was independently assessed by the
investigators, using the Cochrane risk-of-bias algorithm
[19] [see Additional file 1: Table S2].
Potentially relevant studies identified 
and titles and abstracts screened
(n= 9168)
Duplicate publications
Non RCTs-PC and non-human studies
removed
(n= 8727)




No outcomes or conditions
(under stress or hypoxia) of interest
(n= 145)
Administration of PDE5i on-demand 










Figure 1 Study flow diagram. PDE5i: phosphodiesterase 5-inhibitors; RCTs: randomized placebo-controlled trials.
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Selected treatment efficacy outcomes were: cardiac
geometry (left ventricular mass index: LVMi, end-diastolic
volume index: EDVi, interventricular septum: IVS,
ventricular transverse diameter: VTD), cardiac perform-
ance (cardiac index; ejection fraction: EF; the ratio of the
early -E- to late -A- ventricular filling velocities: E/A
ratio), neuroendocrine biomarkers (NT-proBNP) and
hemodynamic/endothelial parameters (heart rate: HR,
blood pressure: BP, systemic vascular resistance index:
SVRi, flow mediated vasodilation: FMD). Information on
adverse events was extrapolated and analyzed to investi-
gate treatment safety.
Data synthesis and analysis
Quantitative data extracted from the papers for all
treatment efficacy outcomes were baseline and after
treatment/placebo means ± standard deviation (SD). When
differences from baseline (means ± SD) were reported, these
were also extracted. When summary statistics were
not adequately or fully reported (for example, missing
pre-post treatment mean difference ± SD on a specific
outcome; standard error of an estimated effect and no
corresponding SD), these were calculated whenever
possible. When baseline levels, post-treatment and/orchange from baseline data were missing or inconsistent,
the authors of the original papers were contacted in order
to obtain the necessary information [see Additional file 1:
Statistical Analysis]. Several studies (16/24) reported data
on mixed populations, male and female; however, only 1
of the 16 contacted authors provided raw data separately
[20], thus it was not possible to stratify by gender.
In order to examine the efficacy of PDE5i in the dif-
ferent clinical settings, all retrieved studies were cate-
gorized a priori according to the following categories:
1) moderate-severe left ventricular hypertrophy (LVH)
versus non/mild-LVH (based on LVMi values above or
below 131 g/m2 [21] and where not available, on NT-
proBNP levels above or below 700 pg/mL) [22]; 2) left
versus right heart disease; 3) cardiac disease versus
non-cardiac disease; 4) HF with reduced EF versus HF
with preserved EF; 5) age: younger versus older than
60 years of age; and 6) active compound: sildenafil versus
tadalafil versus vardenafil. The same categories were also
used for the subgroup analysis. A minimum of two studies
were used for subgroup analyses; however, findings
stemming from such analyses were interpreted with
care. Where a specific subgroup involved a single study,
as occurred for HF with preserved EF [14], the analysis
was not performed.
Table 1 Characteristics of studies selected for analysis
Study Design Condition Treatment Dose and time Number ofpatients (PP)
Mean age (SD) or
age range
Aldashev AA, Thorax, 2005 [26] R, DB, PC HAPH S
25 mg x 3/die 9S versus 8P
61 (8)
100 mg x 3/die 12 we s 5S versus 8P
Amin A, Congest Heart Fail, 2013 [38] R, DB, PC HFrEF S




50 mg x 3/die - >10 w eks P: 50.61 (4.18)
Andersen MJ, Circulation, 2013 [10] R, DB, PC Diastolic Dysfunction after MI S 40 mg x 3/die 9 week 34S versus 33P
S: 63 (8)
P: 62 (7)
Badesch, J Rheumatol, 2007 [27] R, DB, PC PAH-CTD S
20 mg x 3/die 21 S S: 52 (15)
40 mg x 3/die 20 S 50 (15)
80 mg x 3/die 19 S 54 (14)
12 weeks 22 P P: 56 (14)
Behling A, J Cardiac Fail, 2008 [23] R, DB, PC CHF S
50 mg x 3/die
11S versus 8P
S: 45 (12)
4 weeks P: 53 (11)
Bharani A, Indian Heart J, 2007 [28]
R, DB, PC PAH due to congenital left
to right shunt
T
20 mg x 3
8 T - P 28 (9.38)
CO (wo:2 wks) 4 weeks
Bocchio M, Atherosclerosis, 2008 [33] R, DB, PC ED VRF T
20 mg every other da
18 T versus 18P
T: 52.05 (8.98)
12 weeks P: 49.61 (12.68)
Galiè N, NEJM, 2005 [2] R, DB, PC PAH S
20 mg x 3/die 65 S S: 47 (14)
40 mg x 3/die 63 S 51 (15)
80 mg x 3/die 65 S 48 (18)
12 weeks 65 P P: 49 (17)
Giannetta E, Circulation, 2012 [11] R, DB, PC Diabetic Cardiomyopathy S
25 + 25+ 50 mg/die
29S versus 25P
S: 60.7 (7.6)
3 months P: 60.2 (8.3)
Goldberg DJ, Circulation, 2011 [36]
R, DB, PC
CHD after Fontan Operation S
20 mg x 3/die
27 S - P 14.9 (5.1)
CO (wo:6 wks) 6 weeks
Goldberg, DJ Pediatr Cardiol, 2012 [37]
R, DB, PC
CHD after Fontan Operation S
20 mg x 3/die
27 S - P 14.9 (5.1)
CO (wo:6 wks) 6 weeks
Groeneweg G, BMC Muscoloskeletan disorders,
2008 [20] R, DB, PC CRPS T





20 mg/die - >8 weeks
Guazzi M, J Am Coll Cardiol, 2007 [24] R, DB, PC CHF S
50 mg x 3/die
23S versus 23P
S: 62 (3)























Table 1 Characteristics of studies selected for analysis (Continued)
Guazzi M, Circulation, 2011 [25] R, DB, PC HFpEF with PAH S
50 mg x 3/die
22S versus 22P 53-79
12 months
Guazzi M, Circ Heart Fail, 2011 [12] R, DB, PC Systolic HF S
50 mg x 3/die
23S versus 22P
S: 60 (4)
12 months P: 61 (4)
Guazzi M, Europ J Heart Failure, 2012 [39] R, DB, PC EOB in HF S
50 mg x 3/die
16S versus 16P
S: 66 (8)
12 months P: 68 (6)
Jing, Z.C, Am J Resp Crit Care Med, 2011 [30] R, DB, PC PAH V
5 mg/die - >4 weeks
43 V versus 16P
S: 32 (12)
then
5 mg x 2/die - >8 we s P: 29 (8)
Lewis GD, Circulation, 2007 [13] R, DB, PC Systolic HF and secondary PAH S
25 to 75 mg x 3/die
17S versus 17P
S: 54 (4)
12 weeks P: 62 (3)
Lewis GD, Circ Heart Fail, 2008 [31] R, DB, PC Systolic HF and secondary PAH S
25 to 75 mg x 3/die
15S versus 15P
S: 54 (4)
12 weeks P: 62 (3)
Rosano G MC, European Urology, 2005 [34] R, DB, PC ED VRF T
20 mg every other da
16 T versus 16P 65.4 (6.3)
4 weeks
Redfield MM, JAMA, 2013 [14] R, DB, PC HFpEF S
20 mg x 3/die - >12 w eks 49S versus 47Pa
62-77then 60 mg x 3/die -> 45S versus 58Pb
12 weeks 95S versus 94Pc
Sastry BKS, JACC, 2004 [32]
R, DB, PC
PAH S
25 to 100 mg x 3/die
20 S - P 16-55
CO (wo:0) 6 weeks
Suntharalingam J, Chest, 2008 [40] R, DB, PC CTEPH S
40 mg x 3/die
8S versus 10P
S: 49.9 (13.1)
12 weeks P: 60 (14.4)
Van AH, J Sex Med, 2005 [35] R, DB, PC ED V
5 to 20 mg/die
175 V versus 175P
V:22-76
12 weeks P: 22-78
apatients for left ventricular mass index (LVMi) and end-diastolic volume index (EDVi); bpatients for systolic blood pressure (SBP); cpatients for N-terminal-pro brai natriuretic peptide (NT-proBNP). CHD: congenital heart
disease; CHF: chronic heart failure; CO: crossover; CRPS: cold complex regional pain syndrome; CTEPH: chronic thromboembolic pulmonary hypertension; DB: dou le-blind; ED VRF: erectile dysfunction vascular risk
factors; EOB: exercise oscillatory breathing; HAPH: high altitude pulmonary hypertension; HF: heart failure; HFpEF: heart failure preserved ejection fraction; HFrEF: eart failure reduced ejection fraction; MI: myocardial
infarction; P: placebo; PAH: pulmonary arterial hypertension; PAH-CTD: pulmonary arterial hypertension-connective tissue diseases; PC: placebo-controlled; PP: pe rotocol analysis; R: randomized; S: sildenafil;
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the placebo group were analyzed by relative risks calcu-
lated on the intention-to-treat population. Any adverse
event found only in one study was not analyzed [see
Additional file 1: Statistical Analysis].
A meta-analysis was performed on all outcomes and
effect sizes were combined to give a pooled estimate of a
weighted mean difference (WMD) between treatment
and placebo, the weights being the reciprocals of the
variance. A random effects model was fitted. This choice
was dictated by the heterogeneity of study characteristics.
The test for heterogeneity was performed and the I2
statistic (low = 30%; moderate = 30% to 75%; high ≥75%)
calculated. All results are shown in Additional file 1-
Heterogeneity.
Along with estimation results, forest plots and funnel
plots were visually inspected in order to more clearly
detect clusters of studies, outlier studies and possible
publication biases.
Statistical significance was set at P <0.05. The software
used for all statistical analysis was STATA/SE V10.
Results
Study selection
Figure 1 shows the literature search process in MEDLINE,
EMBASE, Cochrane and SCOPUS (March 2012 to
December 2013 and updated in May 2014). We identified
9,168 studies as potentially relevant. Of these, 8,727 were
excluded based on title and abstract content and 417/441
were excluded after full text analysis due to: non-English
language, non-human studies, not RCTs, no outcome of
interest, PDE5i co-administered with other drugs. RCTs
with PDE5i given on demand or for less than 30 consecu-
tive days were excluded. A total of 24 RCTs were eligible
and included in the review (18 administering sildenafil, 4
tadalafil and 2 vardenafil).
Study characteristics
Table 1 summarizes the 24 reports that met all inclusion
criteria. Authors analyzed the effects of continuous PDE5i
administration in various cardiac disorders (diastolic
dysfunction secondary to myocardial infarction [10], HF
[12,14,23-25], PAH [26-32], diabetic cardiomyopathy
[11]) and ED [33-35]. One study was performed on a
non-cardiological/non-urological condition, enrolling
patients with complex regional pain syndrome [20].
Goldberg et al. [36,37] and Lewis et al. [13,31] reported
their results in two separate publications, each addressing
different endpoints; thus, the 24 retrieved papers de-
scribed 22 groups of subjects. For parameters reported
twice (mean BP, SVR and HR), data from the most recent
publications were used [31,37].
Selected trials gave details of 1,622 subjects, with 954
randomized to PDE5i (694 to sildenafil; 54 to tadalafil;218 to vardenafil), and 772 to placebo (per protocol (PP)
analysis), 55 allocated in cross-over trials. Most studies
were performed in North America or Europe, with five
in Asia [26,28,30,32,38].
The studies varied in terms of: 1) daily dosage: some
administered PDE5i with a titration scheme [20,30,38]
or based on individual response [14,32,35]; 2) length of
treatment: from 4-week to 12-month study periods; 3)
endpoint assessment method; 4) age; 5) baseline cardio-
vascular status; and 6) gender: 8 trials enrolled only males
[11,12,24,26,33-35,39], and 16 trials a mixed population of
540 females and 459 males (ITT population). All studies
were RCTs, double-blind (DB) and placebo-controlled.
Four studies were crossover with variable washout periods
(from 0 to 6 weeks) [28,32,36,37].
Around half (56%) of the trials reported cardiovascular
data as secondary outcomes. Fourteen trials received
funding from pharmaceutical companies (Pfizer, Eli Lilly)
[2,13,20,23,26,30,31,34] or foundations [12,25,36,37,39].Risk of bias
All publications reported results from RCTs; however,
the randomization method and allocation concealment
were inappropriately described in 54% of studies (13/24),
so the risk of selection bias was unclear for this group,
while for the remaining 46% of trials the risk of selection
bias was low.
Regarding the reporting bias, seven studies had high
risk and in two additional studies it was unclear. Most
studies had a low risk of performance, detection and attri-
tion bias [see Additional file 1: Risk of bias and Table S2].Synthesis of results
Efficacy data: PDE-5 inhibitors versus placebo
Cardiac geometry The following parameters were con-
sidered measures of cardiac structure: LVMi, EDVi, IVS
and VTD.
LVMi did not change (−4.022 g/m2; 95% CI: −10.137;
2.093, P = 0.20) in the main analysis performed in five
trials, all using sildenafil [10-12,14,25] (n = 306; 72%
male). However, a significant reduction in LVMi (12.207
g/m2; 95% CI: −18.846; −5.568, P <0.001) was detected
in subgroup analysis of patients with left ventricular
hypertrophy (Figure 2).
Similarly, the main analysis of EDVi (0.433 mL/m2;
95% CI: −6.49; 7.357, P = 0.90) in four studies [10-12,14]
(n = 262; 71% male) found no significant change. Sub-
group analyses revealed a significant increase in EDVi in
non-hypertrophic patients (4.999 mL/m2; 95% CI: 3.286;
6.711, P <0.001, I2 = 0.0%) (Figure 2).
The main analysis of IVS [11,25] and VDT [11,12] was
possible in two studies only, with no significant change
found (Table 2).
Figure 2 Effects of PDE5i over placebo on cardiac geometry parameters. A) LVMi main analysis; B) LVMi subgroup analysis in patients with
LVH; C) EDVi main analysis. Diamond indicates the overall summary estimate for the analysis (width of the diamond represents the 95% CI);
boxes, the weight of individual studies in the pooled analysis. EDVi: end-diastolic volume index; LVH: left ventricular hypertrophy; LVMi: left
ventricular mass index; PDE5i: phosphodiesterase type 5 inhibitors.
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WMD −4.022 0.433 −0.966 −2.666 0.304 3.561 0.053 −161.9 −0.848 −0.413 0.616 −0.763 −88.34 3.306
Lower 95% CI −10.137 −6.49 −2.230 −7.145 0.202 1.786 −0.275 −351.5 −2.398 −3.023 −1.113 −2.174 −255.75 0.530
Upper 95% CI 2.093 7.357 0.298 1.814 0.406 5.335 0.380 27.6 0.702 2.196 2.345 0.648 79.08 6.082
—— —— —— —— —— —— —— —— —— —— —— —— —— —— —
Number 306 262 98 99 520 286 116 407 977 355 828 791 232 168
P value 0.197 0.902 0.134 0.243 <0.001 <0.001 0.753 0.094 0.283 0.756 0.490 0.289 0.301 0.020
I-square 96% 94% 95% 90% 0.0% 84% 93% 82% 56% 71% 49% 52% 89% 99%








































LVH −12.207 0.082 4.382 0.053 −486.7 0.829 1.156 0.135 −1.936 55.63 /
Lower 95% CI −18.846 / / / −0.176 2.059 −0.275 −712,8 −4.526 −2.398 −2.598 −5.309 1.438 −277.86
Upper 95% CI −5.568 0.341 6.705 0.380 −260,7 6.185 4.710 2.867 —— 389.12
— —— —— —— —— —— —— —— —— ——
Number 89 62 119 116 97 57 74 72 116 74
P value <0.001 / / / 0.534 <0.001 0.753 <0.001 0.761 0.524 0.923 0.261 0.744 /
I-square 88% / / / 0.0% 79% 93% 0.0% 0.0% 0.0% 0.0% 66% 88% /
Non-LVH 1.404 4.999a 0.354 0.973 −11.20 0.691 0.613 −0.635 / /
Lower 95% CI −1.908 3.286 / / 0.165 −1.329 / −160.8 −2.330 / −5.161 −9.278 8.008
Upper 95% CI 4.717 6.711 0.544 3.274 138.4 3.713 6.388 ——
—— —— —— —— —— —— —— ——
Number 217 217 121 121 310 121 224 121
P value 0.406 <0.001 / / <0.001 0.408 / 0.883 0.654 / 0.835 0.886 / /
I-square 80% 0.0% / / 0.0% 0.0% / 75% 0.0% / 79% 91% / /
Left heart
disease
−4.022 0.433 −0.966 −2.666 0.298 3.561 0.053 −149.7a 0.651 −0.951 0.079a −1.352 −70.97 2.686
















−3.932 1.227 −273.90 −2.635
8.008
Upper 95% CI 0.461 0.380 53.0 131.95
—— —— —— —— —— —— —— —— —— —— —— —— —— —— ——
Number 306 262 98 99 165 286 116 389 229 252 419 360 173 100
P value 0.197 0.902 0.134 0.243 <0.001 <0.001 0.753 0.148 0.710 0.586 0.954 0.304 0.493 0.322


















































Lower 95% CI / / / / 0.178 / / / −4.554 / / −2.637 4.372 / /
Upper 95% CI 0.439 −0.847
—— —— —— ——
Number 355 347 30
P value / / / / <0.001 / / / 0.004 / / 0.628 / /
I-square / / / / 0.0% / / / 0.0% / / 0.0% / /
Non-cardiac
disease
−0.109 0.107 0.073 3.953
Lower 95% CI / / / / / / / / −2.723 / −2.287 −1.515 1.660 / 1.240
Upper 95% CI 2.504 2.502 6.667
—— —— —— —— ——
Number 374 374 374 68
P value / / / / / / / / 0.935 / 0.930 0.928 / 0.004
I-square / / / / / / / / 0.0% / 0.0% 0.0% / 96%
Age <60 yrs 0.284 3.187 0.173a 1.940 −0.008 −0.292 −130.44
Lower 95% CI 0.163 −0.716 −0.150 −0.824 −2.023 −1.631 1.047 −234.44 /
Upper 95% CI / / / / 0.405 7.089 0.496 / / 4.704 2.006 —— −26.43
—— —— —— —— —— —— 513 ——
Number 399 74 71 212 513 89
P value / / / / 0.000 0.110 0.295 / / 0.196 0.993 0.669 0.014 /
I-square / / / / 0.0% 80% 90% / / 0.0% 0.0% 0.0% 0.0% /
Age ≥60 yrs −2.683a 0.433 −2.666 0.354 2.582 −40.199a −0.491 −2.349 0.663 −2.048 −57.48 3.558a
Lower 95% CI −9.169 −6.49 / −7.145
1.814
0.165 −1.074 / −196.023 −3.826 −5.851 −2.067 −4.741 0.646 −349.32 0.306
Upper 95% CI 3.804 7.357 —— 0.544 6.237 115.624 2.844 1.153 3.392 234.36 6.809
—— —— —— —— —— —— —— —— —— —— —— ——
Nymber 262 262 99 121 167 355 221 143 315 234 143 132
P value 0.418 0.902 / 0.243 <0.001 0.166 / 0.613 0.773 0.189 0.634 0.136 0.699 0.032















































Sildenafil −4.022 0.433 −0.966 −2.666 0.289a 3.561 0.053 −161.9 −0.943 −0.880a 0.248 −0.995 −70.9 2.7
Lower 95% CI −10.137 −6.49 −2.230 −7.145
1.814
0.179 1.786 −0.275 −351.5 −2.959 −3.642 −2.138 −2.852 0.863 −273.9 −2.6
Upper 95% CI 2.093 7.357 0.298 0.399 5.335 0.380 27.6 1.073 1.882 2.634 131.9 8.0
— —— —— —— —— —— —— —— —— —— —— —— —— —— ——
Number 306 262 98 99 461 286 116 407 536 296 446 409 173 100
P value 0.197 0.902 0.134 0.243 <0.001 <0.001 0.753 0.094 0.359 0.532 0.839 0.294 0.493 0.322
I-square 96% 94% 95% 90% 0.0% 84% 93% 82% 0.0% 72% 60% 63% 91% /
Tadalafil −1.033 4.659 1.101 3.953
Lower 95% CI −7.141 −2.529 / 1.240
Upper 95% CI / / / / / / / / 5.075 / 11.846 −4.717 6.920 6.667
— —— —— —— ——
Number 32 32 32 68
P value / / / / / / / / 0.740 / 0.204 0.711 / 0.004
I-square / / / / / / / / 0.0% / 0.0% 0.0% / /
Vardenafil −0.408
Lower 95% CI −3.746
Upper 95% CI / / / / / / / / 2.931 / / / / /
— ——
Number 409
P value / / / / / / / / 0.811 / / / / /
I-square / / / / / / / / 0.0% / / / / /
aSensitivity analysis. CI: confidence interval; DBP: diastolic blood pressure; EDVi: end-diastolic volume index; EF: ejection fraction; E/A ratio: the ratio of the early (E) to late (A) ventricular filling velocities; FMD:
flow mediated dilation; HR: heart rate; IVS: interventricular septum; LVH: left ventricular hypertrophy; LVMi: left ventricular mass index; MAP: mean arterial blood pressure; NTpro-BNP: N-terminal-pro brain
natriuretic peptide; SBP: systolic blood pressure; SVRi: systemic vascular resistance index; VTD: ventricular transverse diameter; WMD: weighted mean difference. Bold indicates when “p” are statistically significant. Italics
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Cardiac index and EF were considered measures of sys-
tolic performance and E/A ratio a measure of diastolic
function.
Data on the cardiac index were available in seven studies
[2,10,11,25,30,32,40] (520 patients, 65.6% male), showing
an increase of 0.304 L/min/m2 (95% CI: 0.202; 0.406,
P <0.001) induced by sildenafil [2,10,11,25,32,40] and
vardenafil [30] over placebo [32] (Figure 3). Subgroup
analyses confirmed the significant effects on the cardiac
index in patients without LVH (0.354 L/min/m2; 95% CI:
0.165; 0.544, P <0.001) and in patients with left (0.298
L/min/m2; 95% CI: 0.134; 0.461, P <0.001) or right heart
disease (0.309 L/min/m2; 95% CI: 0.178; 0.438, P <0.001).
The PDE5i-dependent increase in the cardiac index was
observed in patients both younger and older than the
age of 60 (Table 2). These results were confirmed when
sensitivity analysis was performed and the study using
vardenafil [30] excluded (0.289 L/min/m2; 95% CI: 0.179;
0.399, P <0.001).
Six studies [10-12,24,25,31] (286 patients, 95.8% male)
gave details on EF in patients with left heart disease, in
whom sildenafil (n = 146) produced a 3.561% (95% CI:
1.786; 5.335) increase over placebo (n = 140, P <0.001)
(Figure 3). Subgroup analyses revealed larger effect sizes
in patients with LVH (4.382%; 95% CI: 2.059; 6.705,
P <0.001). The meta-analysis of E/A ratio included
three studies [12,25,37] (116 patients, 83.7% male) and
showed no significant effect of sildenafil over placebo.Neuroendocrine biomarkers
NT-proBNP did not change (−161.9 pg/mL; 95%
CI: −351.5; 27.6, P = 0.10) in six trials [10-14,40] (n = 407;
76% male, all treated with sildenafil or placebo). Subgroup
analysis showed a significant decrease in NT-proBNP
levels in patients with LVH (486.7 pg/mL; 95% CI: −712.8;
−260.7, P <0.001) (Figure 4).Hemodynamic parameters
PDE5i administration had no effect on HR in the main
analysis (n = 977, 71% male) [2,10,11,20,24,26,28,30,31,35,
37,39] (Figure 5). In the subgroup analysis a significant
decrease in HR was found in patients with right heart
disease (2.7 bpm; CI: −4.5; −0.8, P = 0.004).
In the 16 analyzed studies (n = 1,012), systolic and
diastolic BP did not change (SBP; +0.616 mmHg; 95%
CI: −1.113; 2.345, P = 0.49; DBP: −0.763 mmHg; 95%
CI: −2.174; 0.648, P = 0.30; MAP: −0.413 mmHg; 95%
CI: −3.023; 2.196, P = 0.80) [10-12,14,20,23-26,28,30,
31,36,38,39] (see Figure 2 and Additional file 1: Figure S1).
Similarly, no change was found in SVRi [10,25,30,31,39]
(n = 232, 71% male) [see Additional file 1: Figure S1]. Sub-
group analysis showed a significant decrease in SVRi onlyin patients younger than 60 (-130.44 dynes m2/sec cm−5;
95% CI: −234.44; −26.43, P = 0.010).
Endothelial function
Four studies [11,24,33,34] (n = 168, all males) showed an
increase in FMD (3.306%; 95% CI: 0.530; 6.082, P = 0.020)
after PDE5i administration over placebo [see Additional
file 1: Figure S2]. Subgroup analysis revealed a higher
effect size in FMD of patients without cardiac disease
treated with tadalafil (3.953%; 95% CI: 1.24; 6.667, P =
0.004). Sensitivity analysis showed a larger effect size
in FMD in patients older than 60 (3.558%; 95% CI:
0.306; 6.809, P = 0.030).
Safety data: PDE-5 inhibitors versus placebo
Adverse events
In our analysis, the adverse events with the highest relative
risks (RRs) related to PDE5i treatment were flushing or
rash (RR = 3.406; 95% CI: 1.628; 7.126, P = 0.001), head-
ache (RR = 2.507; 95% CI: 1.416; 4.439, P = 0.002), gastric
symptoms (RR = 4.138; 95% CI: 1.564; 10.946, P = 0.004)
and epistaxis (RR = 4.701; 95% CI: 1.314; 16.812, P = 0.017)
[see Additional file 1: Table S3]. No significant risk was
observed in other reported side effects including: intestinal
and musculoskeletal symptoms, nasopharyngitis, dizziness
or tinnitus, visual disturbance and photosensitivity, skin
irritation, insomnia, pruritus and dyspnea. The incidence
of symptomatic hypotension and other serious adverse
events was not statistically different between PDE5i and
placebo treated groups.
Discussion
This meta-analysis suggests for the first time that long-
term daily PDE5i administration in mixed study popu-
lations: (1) exerts an anti-remodeling effect on cardiac
geometry in patients with moderate-severe LVH, and
(2) improves cardiac performance in all subjects with
different clinical settings, with (3) no major changes in
hemodynamic parameters and (4) a good safety profile.
This analysis clarifies the discrepancies in previous trials
and suggests that PDE5i is efficacious in cardiac protec-
tion in different stages of heart disease.
Effect of PDE5i on cardiac geometry
The main analysis performed on all studies found no
consistent changes in cardiac geometry. In the few studies
performed on patients with severe LVH, PDE5i decreased
LVMi (−12.207 g/m2; CI: −18.846 to −5.568, P <0.001),
with the limitation being the small number of treated
subjects. Nevertheless, the size of this reduction seems
to be clinically relevant if compared to other anti-
remodeling drugs such as ACEi (angiotensin converting
enzyme inhibitors), ARBs (angiotensin II receptor blockers)
or spironolactone, that have been shown to decrease LVMi,
A B
C D
Figure 3 Effects of PDE5i over placebo on cardiac performance and blood pressure. A) Main analysis on the cardiac index (L/min/m2); B)
Main analysis on EF (%); C) main analysis on SBP (mmHg) and D) main analysis on DPB (mmHg). Diamond indicates the overall summary estimate for
the analysis (width of the diamond represents the 95% CI); boxes indicate the weight of individual studies in the pooled analysis. CI: confidence
interval; PDE5i: phosphodiesterase type 5 inhibitors.
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11 g/m2 in patients with congestive HF [42]. Therefore,
as observed in animal studies [9], our meta-analysis shows
that in human LVH, chronic sildenafil improves cardiac
geometry to an extent comparable to that of currently
recommended anti-remodeling therapies, whereas in
patients with normal or near-normal LVMi, PDE5i
produced no measurable change in cardiac mass.
Of note is the high heterogeneity emerging from the
main analysis (I2 = 96%, P <0.001), that improved when
the studies were stratified according to the degree of car-
diac hypertrophy at baseline (LVH: I2 = 88%, P = 0.003;
non/mild LVH: I2 = 80%, P = 0.005). In addition, inconsist-
encies in the response to treatment seem related to the
study duration. In the two trials lasting less than six
months [10,11], LVMi apparently increased (+3.011 g/m2;
CI −0.506 to 5.515; P = 0.018). Specifically, Andersen et al.
enrolled subjects immediately after an acute myocardial
infarction and the within-subject analysis showed no
significant LVMi changes in either sildenafil (baseline:93 ± 19 g/m2, post-treatment: 95 ± 20 g/m2) or placebo
(baseline 93 ± 20 g/m2, post-treatment 91 ± 18 g/m2)
treated subjects. However, given the opposite trends,
the calculated WMD returned a positive effect. PDE5i
have been shown to exert cardio-protection against post-
ischemic fibrosis [6] and the post-acute setting of this
study could account for the observed WMD (Figure 2).
In contrast, Giannetta et al. enrolled type 2 diabetic
patients with an increased LVMi (119.4 ± 25.7 g/m2),
that did not change after sildenafil or placebo (respectively,
−0.67 ± 5.07 g/m2 and -2.03 ± 7.64 g/m2). For all these
reasons, the observed LVMi variation in this subgroup of
studies could not be considered clinically relevant.
In the three studies lasting more than six months
[12,14,25], LVMi decreased to a much greater extent
(-8.446 g/m2; 95% CI −15.694 to −1.197; P = 0.022). The
two studies by Guazzi et al. were performed in differ-
ent populations with severe LVH due to HF of various
etiologies (baseline LVMi = 166.4 ± 12.1 g/m2 [25] and
147.2 ± 30.2 g/m2 [12]) and were analyzed along with
Figure 4 Effects of PDE5i over placebo on marker of cardiac hypertrophy. A) NT-proBNP in main and B) subgroup analyses for LVH patients.
Diamond indicates the overall summary estimate for the analysis (width of the diamond represents the 95% CI); boxes indicate the weight of individual
studies in the pooled analysis. CI: confidence interval; LVH; left ventricular hypertrophy; N-proBNP: N-terminal-pro brain natriuretic peptide; PDE5i:
phosphodiesterase type 5 inhibitors.
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jects (baseline LVMi = 65 g/m2; interquartile range (IQR):
54 to 78) [14]. Based on these findings, it is reasonable to
assume that a certain duration of treatment and a degree
of hypertrophy are necessary to observe a change in the
cardiac mass as compared to changes in other geometric(EDV) and functional (EF) parameters, that might occur
earlier. Length of treatment and degree of hypertrophy
offer a clinical explanation to the apparently conflicting
findings of the main analysis.
Cardiac remodeling is also measured with the volume-to-
mass ratio known as the concentricity index (LVM/EDV)
Figure 5 Effects of PDE5i on heart rate. A) Main analysis on heart rate (HR); B) subgroup analysis on patients with right heart disease.
Diamond indicates the overall summary estimate for the analysis (width of the diamond represents the 95% CI); boxes indicate the weight of
individual studies in the pooled analysis. CI: confidence interval; PDE5i: phosphodiesterase type 5 inhibitors.
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(I2 = 94%; P <0.001), but when restricting the analysis to
non/mild LVH it dropped to 0% (P = 0.53). The apparently
contradictory findings are probably explained by the signifi-
cant differences in the characteristics of the enrolled studypopulations. The study by Guazzi et al. was the only study
performed in subjects with ventricle dilatation and reduced
EF (severe LVH heart failure); in fact, in the sensitivity
analysis performed in non/mild-LVH patients, we de-
tected a significant increase in EDVi (4.999 mL/m2; 95%
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increase in the final stages of heart failure (eccentric
hypertrophy), but may also drop in the earlier stages of
mild hypertrophy (concentric hypertrophy), we believe
that it is clinically meaningful to attribute the observed
EDVi change in the three homogeneous studies to
improved relaxation of the ventricular wall. Notably, the
LVM/EDV ratio in all of these trials was consistent with
a ‘concentric thick LVH’ pattern [10,11,14], suggesting
that at this earlier stage PDE5i improves myocardial wall
viscoelastic properties resulting in a better diastolic load.
Effect of PDE5i on cardiac performance
Our main analysis reveals for the first time a statistically
and clinically meaningful improvement in cardiac perform-
ance, cardiac index and EF.
In our main analysis, the cardiac index improves
under PDE5i with no heterogeneity between the studies
(I2 = 0.0%), despite the differences in the baseline char-
acteristics of the sample analyzed.
After dividing the sample according to the cardiovascu-
lar features, the subgroup analyses confirmed that PDE5i
increases the cardiac index by 0.3 L/min/m2 in non-LVH
patients. In LVH patients the increase in the cardiac index
does not reach statistical significance. However, this result
is probably due to the paucity of available data, with
only two studies [25,40] involving a total of 62 sub-
jects, one of which was performed in men with chronic
thromboembolic pulmonary hypertension.
In the main analysis, EF also improves, but with highly
significant heterogeneity (I2 84%). Pooling studies accord-
ing to LVH, we observed that in subjects with LVH
the improvement in EF was greater and with lower
heterogeneity (4.38%, CI: 2.059; 6.705, P <0.001; I2 = 79%),
comparable to the average change obtained in large trials
using the currently recommended therapies for HF. A
recent meta-analysis [44] comparing different beta blockers
in HF with reduced EF reported a WMD for EF of 4.1%
(95% CI: 3.1; 4.9) versus placebo/standard treatment. Con-
versely, in non-hypertrophic subjects with preserved EF the
change was not statistically significant (0.973%, CI: -1.329;
3.274, P <0.408; I2 = 0.0%). These results are consistent with
the fact that the PDE5 enzyme is expressed at low levels
within cardiomyocytes, until LVH hypertrophy and failure
develop [45]. Our data show that only when the com-
pensatory mechanisms evolve into changes in cardiac
geometry [14,25] do the benefits of PDE5i on EF become
clinically detectable.
A possible explanation for the observed heterogeneity
is that PDE5 inhibitors work only when the target enzyme
is overexpressed, a condition that parallels the degree of
hypertrophy [see Additional file 1- Limitations]. In addition,
the cardiac index, a more stable measure of cardiac per-
formance, being a function of both chambers’ volumes andcontractility, showed no significant heterogeneity for both
the main and subgroup analyses. A recent analysis reported
PDE5i-induced changes in EF in HF patients [46]. However,
it omitted some relevant studies [25,31] and misclassified
one trial [25], undermining the relevance of the findings.
This led to incomplete data and methodological flaws when
the authors attempted to perform a sub-group analysis
within a group of just two studies. As EF and the cardiac
index depend on cardiac contractility, hemodynamics and
HR, the fact that we found no significant changes in
hemodynamics and HR suggests that the improvement
in cardiac performance observed in patients with left
heart disease [10,11,25] is the result of a PDE5i-mediated
effect on cardiac contractility, while in patients with right
heart disease a dual mechanism of better pulmonary
hemodynamics/oxygenation and improved inotropy is
likely to occur.
One novelty of our work is its parallel analysis, for the
first time, of the changes induced in cardiac geometry
and performance, allowing an appraisal of the direct
myocardial action of PDE5i in humans; until now, this had
been considered merely secondary to indirect systemic/
pulmonary hemodynamic changes.
Neuroendocrine biomarkers
Analyses on NT-proBNP level, an indicator of myocardial
stretch [47], follow the trend observed for ventricular
mass and diastolic function [48,49], with a significant
improvement in the subgroup of hypertrophic patients.
Effect of PDE5i on hemodynamic parameters and
endothelial function
No statistically significant chronotropic effect was found
for PDE5i in the main analysis, except for the subgroup
of patients with right heart disease [see Additional file 1:
Figure S1], where PDE5i reduced HR, without hetero-
geneity (see Table 2 and Additional file 1- Heterogeneity).
For this group, the finding could be explained in terms
of better oxygenation. The chronotropic effects of PDE5i
have never been investigated, but a previous human study
shows that sildenafil can blunt beta-adrenergic stimulation
[50] and the findings are also consistent with a general im-
provement in cardiac contractility [51]. A reduction of just
5 bpm in patients with HF has been associated with a
lower risk of cardiovascular death and hospitalization [51],
but drugs with a proven negative chronotropic effect, such
as beta-blockers, produce HR reductions in the 8- to15-
bpm range [51].
Regarding the effects of PDE5i on BP, our analysis
shows that PDE5i given in a continuous regimen have
no sustained effects on systemic BP, in a large group of
disorders. This effect is confirmed by the absence of any
relevant effect of PDE5i on SVRi in the main analysis.
Our results confirm the findings described in men with
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hypothesis of a coronary steal syndrome due to PDE5i-
related vasodilation was excluded using cardiac cathe-
terism, and are consistent with those of a smaller
meta-analysis [53].
Analysis of the little data available on endothelial
function [11,12,34] seems to confirm a beneficial effect
of continuous treatment with PDE5i, although the data
were almost entirely derived from ED patients [54,55], the
effects did not reach statistical significance in patients with
left heart disease, and there was very high heterogeneity
(I2 = 99%, P <0.001). Only the smallest [33] of the four
trials analyzed is within the 95% CIs, and no relevant
improvement was obtained by subgroup or sensitivity
analysis [see Additional file 1-Heterogeneity], thus limiting
the validity of the findings.
Adverse events
Our analysis of the side effects of long-term daily use of
PDE5i showed that only flushing, headache, epistaxis
and gastric symptoms are statistically related to these drugs,
confirming their cardiovascular safety and good tolerability.
This is relevant in case future studies are planned to test
PDE5i for cardiovascular disorders. It is worth noting that
the majority of retrieved studies were performed in aging
subjects, supporting the safety profile of these drugs when
administered as a daily or continuous regimen even in this
age group.
Limitations
Our review has some limitations. The first concerns the
differences in the baseline characteristics. Subgroup ana-
lyses for length of treatment (less than or more than six
months) were not possible due to the small number of
studies. Similarly, the majority of eligible trials provided
data obtained in patients older than 60 years, using silden-
afil. Furthermore, the lack of data on gender differences in
cardiac outcomes did not permit the exploration of male
and female behavior, whereas there have been significant
advances with respect to cardiovascular disease in women
in the last decade [56].
The second limitation pertains to the often missing infor-
mation on cardiac geometry parameters; while considering
that for all outcomes, 25% of trials had a risk of reporting
bias.
The third concern is that the findings of this study are
nonetheless prone to publication bias and that 13 out of
24 trials had unclear potential for selection bias (although
none with a high risk), that may threaten their validity. On
the positive side, industrial bias seems limited, as most
trials were spontaneous studies that received only external
support. The fact that some studies did not report data on
all basic outcomes reinforces the value of the COMET ini-
tiative aimed at defining the minimum standardized set ofoutcomes that each clinical trial should report for specific
health conditions [57].
A fourth concern is on the high heterogeneity found
in the main analysis. In most, but not all, cases, this was
reasonably explained by the inclusion criteria of the trials,
degree of hypertrophy and chamber dilation, or by dur-
ation of treatment.
Finally, conclusions drawn from subgroup analyses con-
sidering only two studies are only indicative and should be
interpreted with care. See specific limitations in Additional
file 1-Limitations.
Conclusions
With respect to the initial purpose of the study, we
showed that in selected cohorts long-term continuous
PDE5i administration can produce clinically meaningful
improvements in cardiac remodeling and performance
with an excellent cardiovascular safety and tolerability
profile even in older patients and under prolonged use.
The findings are based on recent RCTs that, albeit well-
performed, involved small and heterogeneous popula-
tions. With these limitations, our analyses suggest that
in humans, in vivo, PDE5i exert anti-remodeling proper-
ties that become evident only when the hypertrophic
trigger results in overexpression of the targeted enzyme
in cardiomyocytes. The effects are initially seen as an
improvement in diastolic function (LVM/EDV ratio) and,
subsequently, as a reduction in LVMi in patients with
moderate to severe LVH. All the above findings occur
without any relevant changes in hemodynamics, as evalu-
ated through systemic BP and SVRi.
Our analyses reveal that the ideal target population to
benefit from PDE5 is patients with HF and LVH. Given
the paucity of published data, on the basis of these en-
couraging findings large clinical trials are urgently needed
on the long-term effects of continuous PDE5i adminis-
tration, focusing on cardiovascular outcomes and sex-
specific response in these patients.Additional file
Additional file 1: Additional statistical analyses, heterogeneity, risk
of bias, limitations, additional tables and figures.
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